Ahead of the curve

Drug Store News: Amici has been in the generic pharmaceutical arena for a number of years, what new developments can you share?

Jessica Collette, senior director, sales & marketing, Amici: This is a very exciting and pivotal point within our growth timeline. As you mentioned, Amici launched as a privately held company in 2014 under the leadership of then CEO, Sandy Greco, and quickly established itself as a modest-sized, reliable partner within the generic industry. 

This past May, Amici was acquired through a private equity-backed asset deal based on its long-term growth potential. Our new CEO, Aron Berke, has an extensive background within the healthcare segment and will leverage his expertise to focus on operations improvements, growth strategy implementation and cost structure initiatives. Amici’s new ownership and leadership aims to streamline our operations, drive innovation, and position us for sustainable success in a competitive landscape. Under our new leadership, we are committed to not only maintaining our high standards but also capitalizing on new opportunities to further our impact and reach.

DSN: That is exciting, what changes took place or are those still to come?

JC: The integration process has been exceptionally smooth, largely thanks to the Amici team, which has remained consistent over the years and is staying in place following the acquisition. Despite being a lean organization, the internal structure and its members collaborate seamlessly, making it one of the most impressive support teams I’ve had the pleasure of working with. There is a genuine family vibe that exists. We support each other—all the teams are cross-trained across the various functions. This ensures external stakeholders are prioritized and allows for individual growth and succession planning within the team.

DSN: DSCSA implementation is just around the corner, how is Amici positioned?

JC: We are ready! Honestly, we were already over 95% compliant across our customer and vendor landscape when I joined in January 2023. 

Amici serialized products and exchanged data long before the onset of interoperability requirements, becoming an industry leader in DSCSA readiness. We were the first to develop and fully implement serialization with our 3PL through our partner Systech. Our collaboration has not only deepened our understanding of the complexities of DSCSA but also improved our joint processes, resulting in new efficiencies in our inventory handling and distribution. 

In fact, Amici was so ahead of curve, we became an educating partner for pilot programs with other businesses who were still developing their own implementations.

DSN: Are there new product launches are on the horizon for Amici you’d like to share?

JC: The most thrilling development for us right now is the substantial capital investment being directed towards Amici’s future pipeline and development initiatives. This infusion of resources is set to accelerate our growth, allowing Amici to deliver more value to patients. Our primary goal is to deliver affordable prescription products to patients while maintaining the highest standards of quality. 

We have always been thoughtful and selective in our product offerings and that approach will remain consistent. 

As a virtual manufacturer, Amici will continue to be discerning in our product selection and choice of manufacturing partners. We take pride in offering a current portfolio that is over 90% TAA compliant, and we will continue to prioritize this in our future launches.